TEVA-PROCTOSONE 1 %
FRAMYCETIN SULFATE : 1 % DIBUCAINE HYDROCHLORIDE : 0.5 % ESCULIN : 1 % HYDROCORTISONE (HYDROCORTISONE ACETATE) : 0.5 % · DIN 02226383 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-PROCTOSONE?
TEVA-PROCTOSONE 1 % contains FRAMYCETIN SULFATE : 1 % DIBUCAINE HYDROCHLORIDE : 0.5 % ESCULIN : 1 % HYDROCORTISONE (HYDROCORTISONE ACETATE) : 0.5 %. It is listed in the Health Canada Drug Product Database under DIN 02226383, held by TEVA CANADA LIMITED, supplied as OINTMENT for RECTAL administration. Health Canada currently lists it as marketed, status dated 22-Jan-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-PROCTOSONE used for?
Reduction of swelling, pain and inflammation of hemorrhoids and rectal lesions; management of proctitis, cryptitis, fissures, fistulas, and pruritus ani; pre- and postoperative care.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is TEVA-PROCTOSONE called?
The same molecule, HYDROCORTISONE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Alfacort | Latin | Bahrain, Saudi Arabia, United Arab Emirates |
| HYDROCORTISON VUAB | Latin | Czechia |
| Dilucort | Latin | South Africa |
| HYDROCORTISONE LEURQUIN | Latin | Morocco |
| Macleods Hydrocortisone Injection | Latin | South Africa |
| Softacort | Latin | Czechia, Iceland |
| Terracortril | Latin | South Africa |
| Acecort | Latin | Norway |
| CANDICORT CREAM | Latin | Saudi Arabia |
| COLIRCUSI H.C WITH NEOM | Latin | Saudi Arabia |
| CORTIDERM | Latin | Bahrain |
| Cortotic Vet | Latin | Iceland |
| Covocort | Latin | South Africa |
| Daktacort | Latin | South Africa |
| EFFICORT HYDROPHILE | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02226383 |
|---|---|
| Brand name | TEVA-PROCTOSONE |
| Generic / active ingredient | FRAMYCETIN SULFATE : 1 % DIBUCAINE HYDROCHLORIDE : 0.5 % ESCULIN : 1 % HYDROCORTISONE (HYDROCORTISONE ACETATE) : 0.5 % |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 1 % |
| Dosage form | OINTMENT |
| Route of administration | RECTAL |
| Schedule | Prescription |
| ATC code | C05AA01 HYDROCORTISONE |
| AHFS class | 84:06.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 22-Jan-2018 |
| Original market date | 1997-02-03 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02226383 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2226383 |
| Brand name | TEVA-PROCTOSONE |
| Active ingredient / INN | FRAMYCETIN SULFATE : 1 % DIBUCAINE HYDROCHLORIDE : 0.5 % ESCULIN : 1 % HYDROCORTISONE (HYDROCORTISONE ACETATE) : 0.5 % |
| ATC code | C05AA01 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C05 |
| AHFS class | 84:06.00 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | TEVA CANADA LIMITED |
How is it administered?
Ointment: Apply small quantity morning, evening, and after bowel movements. Suppositories: One suppository morning, evening, and after bowel movements.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 15°-30°C.
How is it supplied?
Ointment: 15 and 30 g tubes with rectal cannula. Suppositories: Boxes of 12.
Which pack is which?
| Strength on the label | 1 % |
|---|---|
| Dosage form | OINTMENT |
| Route | RECTAL |
| Packaging as described in the monograph | Ointment: 15 and 30 g tubes with rectal cannula. Suppositories: Boxes of 12. |
| Storage | Store between 15°-30°C. |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Tuberculosis, fungal and viral infections. Sensitivity to any of the components.
Warnings and precautions
Discontinue if sensitization occurs. Complete proctologic examination before use. Prolonged use may produce systemic corticosteroid effects. Risk of drug-resistant bacteria with misuse.
What can be used instead?
Other Canadian products sharing ATC code C05AA01 HYDROCORTISONE. 10 of 32 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ANODAN-HC 10MG SUPPOSITORIES | 10 MG | SUPPOSITORY | ODAN LABORATORIES LTD | MARKETED | DIN 02236399 |
| ANODAN-HC OINTMENT | 0.5 % | OINTMENT | ODAN LABORATORIES LTD | MARKETED | DIN 02128446 |
| ANUSOL-HC OINTMENT | 0.5 % | OINTMENT | CHURCH & DWIGHT CANADA CORP | MARKETED | DIN 00505773 |
| ANUSOL-HC SUPPOSITORIES | 10 MG | SUPPOSITORY | CHURCH & DWIGHT CANADA CORP | MARKETED | DIN 00476285 |
| JAMPZINC-HC | 0.5 % | OINTMENT | JAMP PHARMA CORPORATION | MARKETED | DIN 02387239 |
| PROCTODAN-HC OINTMENT | 1 % | OINTMENT | ODAN LABORATORIES LTD | MARKETED | DIN 02234466 |
| PROCTODAN-HC SUPPOSITORIES | 10 MG | SUPPOSITORY | ODAN LABORATORIES LTD | MARKETED | DIN 02240851 |
| PROCTOL OINTMENT | 0.5 % | OINTMENT | ODAN LABORATORIES LTD | MARKETED | DIN 02247322 |
| PROCTOL SUPPOSITORIES | 10 MG | SUPPOSITORY | ODAN LABORATORIES LTD | MARKETED | DIN 02247882 |
| EGOZINC-HC | 0.5 % | OINTMENT | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 02209764 |
Who else supplies HYDROCORTISONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. HYDROCORTISONE appears in 37 registered pack listings across 7 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does HYDROCORTISONE cost around the world?
HYDROCORTISONE is listed on 15 national price registers Nexara tracks, across 183 pack listings published on 14 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 11 | 71 | 03 Sep 2026 |
| South Africa | single exit price | 15 | 22 | 01 Sep 2026 |
| Saudi Arabia | public | 16 | 16 | 01 Sep 2026 |
| Greece | producer price (ex-factory) | 15 | 15 | 03 Sep 2026 |
| Austria | KVP (Kassenverkaufspreis) | 9 | 9 | 03 Sep 2026 |
| Czechia | max producer price (ex-factory) | 5 | 9 | 03 Sep 2026 |
| Australia | ex-manufacturer | 4 | 8 | 08 Sep 2026 |
| United Arab Emirates | public | 4 | 6 | 31 Aug 2026 |
| Bahrain | retail (max) | 4 | 6 | 01 Sep 2026 |
| Morocco | PPV (public price) | 5 | 6 | 05 Sep 2026 |
| United Kingdom | hospital | 5 | 5 | 31 Aug 2026 |
| Luxembourg | reimbursement | 4 | 4 | 05 Sep 2026 |
| Iceland | max wholesale | 3 | 3 | 02 Sep 2026 |
| Norway | max AUP (pharmacy retail) | 2 | 2 | 07 Sep 2026 |
| Lebanon | public price (USD, Decision 119/1) | 1 | 1 | 02 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.